Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,800
Closed -$434K 3434
2025
Q4
$434K Sell
1,800
-6,400
-78% -$1.64M ﹤0.01% 2584
2025
Q3
$2.24M Buy
8,200
+5,800
+242% +$1.58M ﹤0.01% 1747
2025
Q2
$619K Sell
2,400
-1,000
-29% -$239K ﹤0.01% 2215
2025
Q1
$761K Sell
3,400
-2,300
-40% -$537K ﹤0.01% 2115
2024
Q4
$1.3M Sell
5,700
-5,800
-50% -$1.4M ﹤0.01% 1841
2024
Q3
$2.81M Buy
+11,500
New +$2.57M ﹤0.01% 1532
2024
Q2
Sell
-2,200
Closed -$436K 3022
2024
Q1
$436K Buy
+2,200
New +$403K ﹤0.01% 2103

Other funds holding RMD

Dmitry Balyasny's RMD Position: Q2 2026 in Review

Dmitry Balyasny increased its ResMed (RMD) stake by 50% in Q2 2026, buying an estimated $227K and bringing the position to 3,291 shares worth $641K. The position accounts for ﹤0.01% of the portfolio, ranked #2419.

Dmitry Balyasny first reported a position in RMD in Q2 2015 and has held it in 25 quarters since. The position peaked at $65.8M in Q4 2021. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Dmitry Balyasny held 3,291 shares of ResMed worth $641K as of Q2 2026.
  • Dmitry Balyasny bought 1,094 ResMed shares in Q2 2026, an estimated $227K.
  • ResMed made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2419 holding.
  • Dmitry Balyasny first reported a position in ResMed in Q2 2015 and has held it in 25 quarters since.
  • Dmitry Balyasny's ResMed position peaked at $65.8M in Q4 2021.
  • 880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.